Anteris Technologies Global Corp.
$4.99-$0.10 (-2.0%)
Last close · Data as of Nov 20, 2026
- Market cap
- $939.4M
- Net margin
- -1685.7%
- ROCE
- -240.8%
Price chart
Technical chartScreen technicals →+47.6% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -20.7%
- 3M
- -46.1%
- 6M
- -42.1%
- 1Y
- +47.6%
- 5Y
- Short history
- A period is left blank when the price history is shorter than the period.
52-week range
Day change -$0.10 (-2.0%) from $5.09 to $4.99 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in AVR, bought on each weekday since 2024.
News & filings
What Anteris Technologies Global filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernEV / Sales of 337.0 is more than ten times the peer median of 1.5.
Strengths (1)
- Current assets are 2.56 times current liabilities.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve.
Read moreShow less
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
- Sector
- Healthcare
- Shares outstanding
- 35.9M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $939.4M
- P/B
- 48.7x
- EV / Sales
- 337.0x
- P/S
- 344.1x
- 52-week high
- $10.57
- 52-week low
- $3.38
Profitability
- Operating margin
- -1709.2%
- Net margin
- -1685.7%
- EBITDA margin
- -1668.1%
- ROE
- -238.4%
- ROCE
- -240.8%
- ROA
- -150.7%
- Asset turnover
- 0.09
Growth
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 0.0%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 0.0%
Solvency
- Current ratio
- 2.56
- Debt / Equity
- 0.09
- Debt / Assets
- 0.06
- CFO / Net profit
- 0.75
- Cash / Market cap
- 2.2%
Revenue and net profit
Revenue grew 0.0% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | $5.8M | -$17.2M |
| FY2022 | $3.2M | -$30.6M |
| FY2023 | $2.7M | -$46.0M |
Cash flows
Cash from operations, with free cash flow as the dashed line.
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | -$14.4M | -$15.0M |
| FY2022 | -$29.4M | -$31.1M |
| FY2023 | -$34.6M | -$37.0M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | — | — | — | — | — | 0.0% | 0.0% |
Monthly returns
Month-by-month returns of AVR across the years, with the seasonal pattern.
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; AVR highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Corvus Pharmaceuticals, Inc., Olema Pharmaceuticals, Inc., Annexon, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Anteris Technologies Global Corp.AVRthis company | $939.4M | — | 48.7x | -238.4% | — |
| Corvus Pharmaceuticals, Inc.CRVS | $985.5M | -64.5x | 16.1x | -25.0% | -22.9x |
| InnovAge Holding Corp.INNV | $977.3M | -32.2x | 4.2x | -12.9% | -102.4x |
| U.S. Physical Therapy, Inc.USPH | $940.1M | 62.4x | 2.0x | 3.2% | 11.1x |
| Olema Pharmaceuticals, Inc.OLMA | $932.9M | -5.7x | 1.9x | -33.9% | -5.0x |
| Nutex Health Inc.NUTX | $929.7M | 13.1x | 2.8x | 21.5% | 3.8x |
| ARS Pharmaceuticals, Inc.SPRY | $900.7M | -5.3x | 7.9x | -149.9% | -5.7x |
| Annexon, Inc.ANNX | $892.9M | -4.3x | 4.2x | -97.7% | -3.5x |
| Pacira BioSciences, Inc.PCRX | $892.0M | 126.9x | 1.3x | 1.0% | 8.7x |
| Peer median | — | -4.8x | 3.5x | -18.9% | -4.3x |
Year-to-date ROI
AVR since 1 January, against earlier years.
Historical volatility
AVR's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | -279.9% |
| FY2022 | -984.1% |
| FY2023 | -1709.2% |
| FY2024 | — |
| FY2025 | — |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | — |
| Cost of revenueCost Of Revenue | — |
| Gross profitGross Profit | — |
| Operating expensesOperating Expense | — |
| Research and developmentResearch And Development | — |
| Selling, general and administrativeSelling General And Administration | — |
| Other operating expensesOther Operating Expenses | — |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | — |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | — |
| Insurance and claimsInsurance And Claims | — |
| Total expensesTotal Expenses | — |
| Operating incomeOperating Income | — |
| Interest and other | |
| Pretax incomePretax Income | — |
| TaxTax Provision | — |
| Net incomeNet Income | — |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | — |
| Current assetsCurrent Assets | — |
| Non-current assetsTotal Non Current Assets | — |
| LiabilitiesTotal Liabilities Net Minority Interest | — |
| Current liabilitiesCurrent Liabilities | — |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | — |
| EquityTotal Equity Gross Minority Interest | — |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | — |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | — |
| Net income, continuing operationsNet Income From Continuing Operations | — |
| Depreciation and amortisationDepreciation And Amortization | — |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | — |
| Depreciation | — |
| Amortization cash flowAmortization Cash Flow | — |
| Amortization of intangiblesAmortization Of Intangibles | — |
| Stock-based compensationStock Based Compensation | — |
| Operating gains and lossesOperating Gains Losses | — |
| Gain loss on investment securitiesGain Loss On Investment Securities | — |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | — |
| Net foreign currency exchange gain lossNet Foreign Currency Exchange Gain Loss | — |
| Change in working capitalChange In Working Capital | — |
| Other non-cash itemsOther Non Cash Items | — |
| Investing cash flowInvesting Cash Flow | — |
| Cash from continuing investingCash Flow From Continuing Investing Activities | — |
| Capital expenditureCapital Expenditure | — |
| Purchase of PP&EPurchase Of PPE | — |
| Sale of PP&ESale Of PPE | — |
| Net PP&E purchases and salesNet PPE Purchase And Sale | — |
| AcquisitionsPurchase Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | — |
| Purchase of investmentsPurchase Of Investment | — |
| Net investment purchases and salesNet Investment Purchase And Sale | — |
| Purchase of intangiblesPurchase Of Intangibles | — |
| Sale of intangiblesSale Of Intangibles | — |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | — |
| Financing cash flowFinancing Cash Flow | — |
| Cash from continuing financingCash Flow From Continuing Financing Activities | — |
| Debt issuedIssuance Of Debt | — |
| Debt repaidRepayment Of Debt | — |
| Net debt issuedNet Issuance Payments Of Debt | — |
| Short-term debt issuedShort Term Debt Issuance | — |
| Short-term debt repaidShort Term Debt Payments | — |
| Net short-term debt issuedNet Short Term Debt Issuance | — |
| Long-term debt repaidLong Term Debt Payments | — |
| Net long-term debt issuedNet Long Term Debt Issuance | — |
| Shares issuedIssuance Of Capital Stock | — |
| Common stock issuedCommon Stock Issuance | — |
| Net common stock issuedNet Common Stock Issuance | — |
| Other financing chargesNet Other Financing Charges | — |
| Change in cashChanges In Cash | — |
| Effect of exchange ratesEffect Of Exchange Rate Changes | — |
| Cash at the start of the yearBeginning Cash Position | — |
| Cash at the end of the yearEnd Cash Position | — |
| Free cash flowFree Cash Flow | — |
| Supplemental |
Learn while you research
Academy chapters picked for Anteris Technologies Global Corp. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read